Neurocrine Plans to Lay Off Half Its Staff

Neurocrine Biosciences, maker of experimental drugs for treating neurological and endocrine disorders, said May 6 it would cut its 120-person staff in half to conserve cash as it focuses on moving its midstage clinical programs into final Phase 3 trials...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

• 52 weekly issues
• Subscriber-only digital content every business day, plus full access to SDBJ.com archives
• Book of Lists — the most comprehensive business resource in San Diego
• San Diego 500 — influential business leaders you need to know

Yours for only $129

First name:

Last name:

Email:

Address:

Zip:

CC Number:

Cvv:

Exp Month:

Exp Year: